Amarin Corp Plc (AMRN)

[nutsyprofessor]

No doubt but they do work! lol, why do you think the Vascepa trials were done with statins? Because it was meant as a supplement to statins and NOT a replacement of statins!!! And that is the issue as to why the FDA might be hesitant to approve a product (Vascepa ANCHOR indication) which has as its whole premise to lower TG's thereby reducing the incidence of CVD. They are concerned that patients might just believe that all they need to do is take Vascepa to address their lipid profile.

Let me ask you a question: what if the REDUCE-IT trial to be completed by 2017 shows that Vascepa does NOT lower the incidence of CVD? There would be lawsuits left and right against the FDA because patients would have been taking Vascepa based on this premise when they could have been taking statins which do work.

There have been no less than 10 trials that have enrolled a total of 70?388 people, of whom 23?681 (34%) were women and with 16?078 (23%) had diabetes mellitus and treated with statins. These had a mean follow-up of 4.1 years. The studies showed significantly reduced risk of all cause mortality (odds ratio 0.88, 95% confidence interval 0.81 to 0.96), major coronary events (0.70, 0.61 to0.81), and major cerebrovascular events (0.81, 0.71 to 0.93). There was no significant heterogeneity of the treatment effect in clinical subgroups.

sts66, once again, your statement below is almost as funny as your "CVD has nothing to do with ANCHOR" statement.